Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 4/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PAM | P19021 | 2/20 | 0.33 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29343911 | 0.90 | DNM1 (0.47) | DNM1PRKCADGKAKDM4EDUSP3 | |
| SCHEMBL29344665 | 0.87 | CYP3A4 (0.43) | PRKCADGKAKDM4EDUSP3MEN1 | |
| SCHEMBL29344610 | 0.86 | DNM1 (0.35) | DNM1PRKCADGKAPAOXKDM4E | |
| SCHEMBL13616522 | 0.84 | DGKA (0.51) | DNM1DGKAKDM4EDUSP3MEN1 | |
| SCHEMBL29344813 | 0.83 | CYP3A4 (0.40) | PRKCADGKAKDM4EDUSP3MEN1 | |
| SCHEMBL27355672 | 0.81 | DNM1 (0.46) | DNM1PRKCADGKAKDM4EDUSP3 | |
| SCHEMBL2776621 | 0.81 | DGKA (0.55) | DNM1PRKCADGKAKDM4EDUSP3 | |
| SCHEMBL29343913 | 0.81 | CYP3A4 (0.47) | DNM1PRKCADGKAKDM4EDUSP3 | |
| SCHEMBL29344873 | 0.80 | — | — | |
| SCHEMBL13332433 | 0.79 | DGKA (0.46) | DNM1PRKCADGKAKDM4EDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | DNM1 883/4885PRKCA 1820/4885DGKA 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.